Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.

Meltzer-Brody S, Colquhoun H, Riesenberg R, Epperson CN, Deligiannidis KM, Rubinow DR, Li H, Sankoh AJ, Clemson C, Schacterle A, Jonas J, Kanes S.

Lancet. 2018 Sep 22;392(10152):1058-1070. doi: 10.1016/S0140-6736(18)31551-4. Epub 2018 Aug 31. Erratum in: Lancet. 2018 Sep 29;392(10153):1116.

PMID:
30177236
2.

Brexanolone as adjunctive therapy in super-refractory status epilepticus.

Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, Hoffmann E, Colquhoun H, Doherty JJ, Kanes SJ.

Ann Neurol. 2017 Sep;82(3):342-352. doi: 10.1002/ana.25008. Epub 2017 Sep 11.

3.

Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.

Kanes S, Colquhoun H, Gunduz-Bruce H, Raines S, Arnold R, Schacterle A, Doherty J, Epperson CN, Deligiannidis KM, Riesenberg R, Hoffmann E, Rubinow D, Jonas J, Paul S, Meltzer-Brody S.

Lancet. 2017 Jul 29;390(10093):480-489. doi: 10.1016/S0140-6736(17)31264-3. Epub 2017 Jun 12.

PMID:
28619476
4.

Open-label, proof-of-concept study of brexanolone in the treatment of severe postpartum depression.

Kanes SJ, Colquhoun H, Doherty J, Raines S, Hoffmann E, Rubinow DR, Meltzer-Brody S.

Hum Psychopharmacol. 2017 Mar;32(2). doi: 10.1002/hup.2576.

5.

Burden of illness for super-refractory status epilepticus patients.

Beg JM, Anderson TD, Francis K, Meckley LM, Fitzhenry D, Foster T, Sukhtankar S, Kanes SJ, Moura LM.

J Med Econ. 2017 Jan;20(1):45-53. Epub 2016 Aug 24.

PMID:
27556834
6.

First Human Study of the Investigational Sedative and Anesthetic Drug AZD3043: A Dose-Escalation Trial to Assess the Safety, Pharmacokinetics, and Efficacy of a 30-Minute Infusion in Healthy Male Volunteers.

Kalman S, Koch P, Ahlén K, Kanes SJ, Barassin S, Björnsson MA, Norberg Å.

Anesth Analg. 2015 Oct;121(4):885-93. doi: 10.1213/ANE.0000000000000831.

PMID:
26111262
7.

A Bolus and Bolus Followed by Infusion Study of AZD3043, an Investigational Intravenous Drug for Sedation and Anesthesia: Safety and Pharmacodynamics in Healthy Male and Female Volunteers.

Norberg Å, Koch P, Kanes SJ, Björnsson MA, Barassin S, Ahlén K, Kalman S.

Anesth Analg. 2015 Oct;121(4):894-903. doi: 10.1213/ANE.0000000000000804.

PMID:
26097986
8.

Pediatric super-refractory status epilepticus treated with allopregnanolone.

Broomall E, Natale JE, Grimason M, Goldstein J, Smith CM, Chang C, Kanes S, Rogawski MA, Wainwright MS.

Ann Neurol. 2014 Dec;76(6):911-5. doi: 10.1002/ana.24295. Epub 2014 Nov 11.

9.

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.

Litman RE, Smith MA, Desai DG, Simpson T, Sweitzer D, Kanes SJ.

J Clin Psychopharmacol. 2014 Apr;34(2):199-204. doi: 10.1097/JCP.0000000000000071.

PMID:
24525659
10.

A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers.

Varnäs K, Jučaite A, McCarthy DJ, Stenkrona P, Nord M, Halldin C, Farde L, Kanes S.

Cephalalgia. 2013 Jul;33(10):853-60. doi: 10.1177/0333102413476372. Epub 2013 Feb 19.

PMID:
23430984
11.

Association of schizophrenia with the phenylthiocarbamide taste receptor haplotype on chromosome 7q.

Moberg PJ, Li M, Kanes SJ, Gur RE, Kamath V, Turetsky BI.

Psychiatr Genet. 2012 Dec;22(6):286-9. doi: 10.1097/YPG.0b013e32835863f0.

PMID:
22955840
12.

Glutamate-based depression GBD.

McCarthy DJ, Alexander R, Smith MA, Pathak S, Kanes S, Lee CM, Sanacora G.

Med Hypotheses. 2012 May;78(5):675-81. doi: 10.1016/j.mehy.2012.02.009. Epub 2012 Mar 4.

PMID:
22391030
13.

Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.

Kelly MP, Stein JM, Vecsey CG, Favilla C, Yang X, Bizily SF, Esposito MF, Wand G, Kanes SJ, Abel T.

Mol Psychiatry. 2009 Apr;14(4):398-415, 347. doi: 10.1038/mp.2008.124. Epub 2008 Nov 25. Erratum in: Mol Psychiatry. 2009 Dec;14(12):1145.

14.

Constitutive activation of the G-protein subunit Galphas within forebrain neurons causes PKA-dependent alterations in fear conditioning and cortical Arc mRNA expression.

Kelly MP, Cheung YF, Favilla C, Siegel SJ, Kanes SJ, Houslay MD, Abel T.

Learn Mem. 2008 Jan 28;15(2):75-83. doi: 10.1101/lm.723708. Print 2008 Feb.

15.

Neurocognitive endophenotypes in a multiplex multigenerational family study of schizophrenia.

Gur RE, Nimgaonkar VL, Almasy L, Calkins ME, Ragland JD, Pogue-Geile MF, Kanes S, Blangero J, Gur RC.

Am J Psychiatry. 2007 May;164(5):813-9.

PMID:
17475741
16.

Visual attention circuitry in schizophrenia investigated with oddball event-related functional magnetic resonance imaging.

Gur RE, Turetsky BI, Loughead J, Snyder W, Kohler C, Elliott M, Pratiwadi R, Ragland JD, Bilker WB, Siegel SJ, Kanes SJ, Arnold SE, Gur RC.

Am J Psychiatry. 2007 Mar;164(3):442-9.

PMID:
17329469
17.

Phenylthiocarbamide (PTC) perception in patients with schizophrenia and first-degree family members: relationship to clinical symptomatology and psychophysical olfactory performance.

Moberg PJ, McGue C, Kanes SJ, Roalf DR, Balderston CC, Gur RE, Kohler CG, Turetsky BI.

Schizophr Res. 2007 Feb;90(1-3):221-8. Epub 2007 Jan 8.

18.

Pharmacokinetic and behavioral characterization of a long-term antipsychotic delivery system in rodents and rabbits.

Metzger KL, Shoemaker JM, Kahn JB, Maxwell CR, Liang Y, Tokarczyk J, Kanes SJ, Hans M, Lowman AM, Dan N, Winey KI, Swerdlow NR, Siegel SJ.

Psychopharmacology (Berl). 2007 Feb;190(2):201-11. Epub 2006 Nov 21.

PMID:
17119931
19.

Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP.

Neuroscience. 2007 Jan 5;144(1):239-46. Epub 2006 Nov 1.

20.

Olfactory functioning in schizophrenia: relationship to clinical, neuropsychological, and volumetric MRI measures.

Moberg PJ, Arnold SE, Doty RL, Gur RE, Balderston CC, Roalf DR, Gur RC, Kohler CG, Kanes SJ, Siegel SJ, Turetsky BI.

J Clin Exp Neuropsychol. 2006 Nov;28(8):1444-61.

PMID:
17050269
21.

Mice expressing constitutively active Gsalpha exhibit stimulus encoding deficits similar to those observed in schizophrenia patients.

Maxwell CR, Liang Y, Kelly MP, Kanes SJ, Abel T, Siegel SJ.

Neuroscience. 2006 Sep 1;141(3):1257-64. Epub 2006 Jun 5.

22.

Constitutive activation of Galphas within forebrain neurons causes deficits in sensorimotor gating because of PKA-dependent decreases in cAMP.

Kelly MP, Isiegas C, Cheung YF, Tokarczyk J, Yang X, Esposito MF, Rapoport DA, Fabian SA, Siegel SJ, Wand G, Houslay MD, Kanes SJ, Abel T.

Neuropsychopharmacology. 2007 Mar;32(3):577-88. Epub 2006 May 31.

23.

Prognostic variables at intake and long-term level of function in schizophrenia.

Siegel SJ, Irani F, Brensinger CM, Kohler CG, Bilker WB, Ragland JD, Kanes SJ, Gur RC, Gur RE.

Am J Psychiatry. 2006 Mar;163(3):433-41.

PMID:
16513864
24.

Levels-of-processing effect on frontotemporal function in schizophrenia during word encoding and recognition.

Ragland JD, Gur RC, Valdez JN, Loughead J, Elliott M, Kohler C, Kanes S, Siegel SJ, Moelter ST, Gur RE.

Am J Psychiatry. 2005 Oct;162(10):1840-8.

25.

Ketamine produces lasting disruptions in encoding of sensory stimuli.

Maxwell CR, Ehrlichman RS, Liang Y, Trief D, Kanes SJ, Karp J, Siegel SJ.

J Pharmacol Exp Ther. 2006 Jan;316(1):315-24. Epub 2005 Sep 28.

PMID:
16192313
26.

Corticosterone modulates auditory gating in mouse.

Maxwell CR, Ehrlichman RS, Liang Y, Gettes DR, Evans DL, Kanes SJ, Abel T, Karp J, Siegel SJ.

Neuropsychopharmacology. 2006 May;31(5):897-903.

27.

Monoamine reuptake inhibition and nicotine receptor antagonism reduce amplitude and gating of auditory evoked potentials.

Siegel SJ, Maxwell CR, Majumdar S, Trief DF, Lerman C, Gur RE, Kanes SJ, Liang Y.

Neuroscience. 2005;133(3):729-38.

PMID:
15908134
28.

Phenylthiocarbamide perception in patients with schizophrenia and first-degree family members.

Moberg PJ, Roalf DR, Balderston CC, Kanes SJ, Gur RE, Turetsky BI.

Am J Psychiatry. 2005 Apr;162(4):788-90.

PMID:
15800154
29.

Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications.

Maxwell CR, Kanes SJ, Abel T, Siegel SJ.

Neuroscience. 2004;129(1):101-7.

PMID:
15489033
30.

Effects of a functional COMT polymorphism on prefrontal cognitive function in patients with 22q11.2 deletion syndrome.

Bearden CE, Jawad AF, Lynch DR, Sokol S, Kanes SJ, McDonald-McGinn DM, Saitta SC, Harris SE, Moss E, Wang PP, Zackai E, Emanuel BS, Simon TJ.

Am J Psychiatry. 2004 Sep;161(9):1700-2.

PMID:
15337663
31.

The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components.

Connolly PM, Maxwell C, Liang Y, Kahn JB, Kanes SJ, Abel T, Gur RE, Turetsky BI, Siegel SJ.

Neurochem Res. 2004 Jun;29(6):1179-88.

PMID:
15176475
32.

Event-related fMRI of frontotemporal activity during word encoding and recognition in schizophrenia.

Ragland JD, Gur RC, Valdez J, Turetsky BI, Elliott M, Kohler C, Siegel S, Kanes S, Gur RE.

Am J Psychiatry. 2004 Jun;161(6):1004-15.

33.

Altered RNA editing of serotonin 5-HT2C receptor induced by interferon: implications for depression associated with cytokine therapy.

Yang W, Wang Q, Kanes SJ, Murray JM, Nishikura K.

Brain Res Mol Brain Res. 2004 Apr 29;124(1):70-8.

PMID:
15093687
34.

A sexually dimorphic ratio of orbitofrontal to amygdala volume is altered in schizophrenia.

Gur RE, Kohler C, Turetsky BI, Siegel SJ, Kanes SJ, Bilker WB, Brennan AR, Gur RC.

Biol Psychiatry. 2004 Mar 1;55(5):512-7.

PMID:
15023579
35.

Patient attitudes towards surgically implantable, long-term delivery of psychiatric medicine.

Irani F, Dankert M, Brensinger C, Bilker WB, Nair SR, Kohler CG, Kanes SJ, Turetsky BI, Moberg PJ, Ragland JD, Gur RC, Gur RE, Siegel SJ.

Neuropsychopharmacology. 2004 May;29(5):960-8.

36.

Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential.

Maxwell CR, Liang Y, Weightman BD, Kanes SJ, Abel T, Gur RE, Turetsky BI, Bilker WB, Lenox RH, Siegel SJ.

Neuropsychopharmacology. 2004 Apr;29(4):739-46.

37.

Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha.

Gould TJ, Bizily SP, Tokarczyk J, Kelly MP, Siegel SJ, Kanes SJ, Abel T.

Neuropsychopharmacology. 2004 Mar;29(3):494-501.

38.

Inhibition of auditory evoked potentials and prepulse inhibition of startle in DBA/2J and DBA/2Hsd inbred mouse substrains.

Connolly PM, Maxwell CR, Kanes SJ, Abel T, Liang Y, Tokarczyk J, Bilker WB, Turetsky BI, Gur RE, Siegel SJ.

Brain Res. 2003 Nov 28;992(1):85-95.

PMID:
14604776
39.

Impairment of odor hedonics in men with schizophrenia.

Moberg PJ, Arnold SE, Doty RL, Kohler C, Kanes S, Seigel S, Gur RE, Turetsky BI.

Am J Psychiatry. 2003 Oct;160(10):1784-9.

PMID:
14514491
40.

Facial emotion recognition in schizophrenia: intensity effects and error pattern.

Kohler CG, Turner TH, Bilker WB, Brensinger CM, Siegel SJ, Kanes SJ, Gur RE, Gur RC.

Am J Psychiatry. 2003 Oct;160(10):1768-74.

PMID:
14514489
41.

Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice.

Siegel SJ, Connolly P, Liang Y, Lenox RH, Gur RE, Bilker WB, Kanes SJ, Turetsky BI.

Neuropsychopharmacology. 2003 Apr;28(4):675-82. Epub 2002 Sep 16.

42.

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

Potenza MN, Holmes JP, Kanes SJ, McDougle CJ.

J Clin Psychopharmacol. 1999 Feb;19(1):37-44.

PMID:
9934941
43.

Imaging D2 receptor occupancy by endogenous dopamine in humans.

Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB.

Neuropsychopharmacology. 1997 Sep;17(3):162-74.

44.

Mapping the genes for haloperidol-induced catalepsy.

Kanes S, Dains K, Cipp L, Gatley J, Hitzemann B, Rasmussen E, Sanderson S, Silverman M, Hitzemann R.

J Pharmacol Exp Ther. 1996 May;277(2):1016-25.

PMID:
8627512
45.

Genetics and the organization of the basal ganglia.

Hitzemann R, Qian Y, Kanes S, Dains K, Hitzemann B.

Int Rev Neurobiol. 1995;38:43-94. Review. No abstract available.

PMID:
8537205
46.

Further studies on the relationship between dopamine cell density and haloperidol-induced catalepsy.

Hitzemann B, Dains K, Kanes S, Hitzemann R.

J Pharmacol Exp Ther. 1994 Nov;271(2):969-76.

PMID:
7965819
47.

On the relationship between D2 receptor density and neuroleptic-induced catalepsy among eight inbred strains of mice.

Kanes SJ, Hitzemann BA, Hitzemann RJ.

J Pharmacol Exp Ther. 1993 Oct;267(1):538-47.

PMID:
7901398

Supplemental Content

Support Center